Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Eczema itch: enzymes aimed at skin bacteria show promise, with mixed early results

☕ Includes a question for the family ↓

EczemaPart of a story we are following · 6 articles · See every update
An older couple laughs together while reading books at home.
An older couple laughs together while reading books at home.Photo: Shixart1985 / Wikimedia Commons, CC BY 2.0

If eczema itch has worn you down, you probably want to know what is coming next. Scientists are studying a new way to go after one of the bacteria linked to that itch. The early results are a mix of promising and unsettled.

In a review of the research on endolysins, which are enzymes made from bacteriophages, scientists found that lab studies support targeting Staphylococcus aureus in atopic dermatitis (the medical name for this kind of eczema), while the first findings in people are mixed.

How the study worked

This is a review, so the authors gathered and weighed earlier research rather than testing a treatment themselves. It was published in the J Invest Dermatol on November 7, 2026. Because it covers early work, many of its questions are still open.

What is an endolysin?

A bacteriophage is a virus that infects bacteria. Endolysins are enzymes that these viruses make. Think of them as tiny scissors. They cut the wall that holds a bacterium together, and the bacterium bursts.

They can do this quickly. They also work without the bacteria needing to be actively growing. Each enzyme goes after a certain range of bacteria, and that range varies from one enzyme to the next.

What they found

The starting point is the skin itself. In atopic dermatitis, long-lasting itch is associated with an imbalance in the skin’s bacteria. Helpful, protective bacteria are lost, and Staphylococcus aureus, often called Staph, expands.

Staph can make itch worse. It releases proteases (enzymes that break down proteins) and toxins. These can switch on the nerves that sense itch, and they can feed the type of inflammation behind eczema.

That is where endolysins come in. Strong antibiotics can wipe out helpful bacteria along with the harmful ones. Endolysins may be more targeted. Studies done before human testing support their ability to go after Staph selectively.

The picture in people is less clear. The review says early clinical findings in atopic dermatitis are mixed. So this approach looks promising on paper and in the lab, but it has not yet proven itself on real skin.

The authors also name several questions that are still open:

  • How to make it. The best form for putting an endolysin on the skin is not settled.
  • Who it fits. It is not yet clear which patients would benefit most.
  • Inflammation from breakdown. When bacteria burst quickly, that can itself stir up inflammation.
  • Leftover toxins. Some toxins may stay active even after the bacteria are killed.

The review also says endolysins should be considered alongside other approaches that work on the skin’s bacteria. One example is putting protective, helpful bacteria back on the skin.

What you can do today

This review does not give you a new step to take, and it does not change current advice. Endolysins are still being studied, so there is nothing new to ask for. Keep following the eczema routine you already have.

For clinicians and researchers

Design: Systematic review of bacteriophage-derived endolysins in atopic dermatitis and other pruritic dermatoses, covering mechanism, preclinical studies and early clinical findings. The abstract gives no number of studies, participants or follow-up.

Main result: Preclinical studies support selective antistaphylococcal activity, but early clinical findings in atopic dermatitis are mixed. No effect size or confidence interval is given in the abstract.

Main limitation: Clinical evidence is early and mixed, and the abstract reports no pooled estimate. Antimicrobial spectrum varies by enzyme, so findings may not generalize across endolysins.

How it fits: Earlier Mongevity articles covered targeted eczema drugs and tapering of eczema medicine; this review addresses a different, microbiome-directed approach to atopic dermatitis. Eczema: newer targeted drugs went with fewer hospital and ER visits · Easing down your eczema medicine often keeps skin calm, review finds

Open question: Unresolved issues include formulation, patient selection, inflammation from rapid bacterial breakdown, and toxins that may remain active after bacterial killing. Comparison with topical bacteriotherapy using protective commensals is also needed.

Talk about it at home

Your skin has lots of tiny living things on it, and many of them are helpers. Scientists found that some viruses make a special tool that pops one kind of bacterium, a bit like a key that fits only one lock. They are testing whether that tool can calm itchy skin without harming the helpers.

Question for the table

What if you had a garden full of flowers and a few weeds, and you could only use a tool that pulls up weeds? What would make that tool hard to design, and how would you check that it left the flowers alone?

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Eczema itch: enzymes aimed at skin bacteria show promise, with mixed early results. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/skin/2026/11/eczema-itch-endolysins-skin-bacteria-review/
Vancouver
Mongevity Desk. Eczema itch: enzymes aimed at skin bacteria show promise, with mixed early results [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/skin/2026/11/eczema-itch-endolysins-skin-bacteria-review/
APA
Mongevity Desk. (2026, November 22). Eczema itch: enzymes aimed at skin bacteria show promise, with mixed early results. Mongevity. https://mongevity.science/skin/2026/11/eczema-itch-endolysins-skin-bacteria-review/
For your website
<a href="https://mongevity.science/skin/2026/11/eczema-itch-endolysins-skin-bacteria-review/">Eczema itch: enzymes aimed at skin bacteria show promise, with mixed early results</a>

Free to share or quote with credit and a link.

Questions and answers

What is an endolysin?
It is an enzyme made by a bacteriophage, a virus that infects bacteria. It cuts the wall of certain bacteria so they burst.
Why does Staph matter in eczema itch?
In atopic dermatitis, Staphylococcus aureus can expand on the skin. It releases proteases and toxins that can activate itch nerves and add to inflammation.
Does it work in people with eczema?
Lab studies support it, but early findings in people with atopic dermatitis are mixed. More work is needed.
Should I change my eczema care because of this review?
No. The review describes a approach still being studied and does not change current advice.

Sources

  1. J Invest Dermatol: Bacteriophage-Derived Endolysins in Atopic Dermatitis and Other Pruritic Dermatoses: Mechanistic Rationale, Clinical Evidence, and Limitations (PMID 42998756 · DOI 10.1016/j.jid.2026.10.037) · 2026-11-22

More on this story

Report an error